# PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery

> **NCT05468138** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 141 (estimated)

## Conditions studied

- MSI-H
- PD-1 Immunotherapy
- Gastric Cancer
- Adjuvant Therapy

## Interventions

- **DRUG:** SOX
- **DRUG:** XELOX
- **OTHER:** Observation
- **DRUG:** PD-1 antibody

## Key facts

- **NCT ID:** NCT05468138
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-25
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2022-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05468138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05468138, "PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05468138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*